KRAS and cancer: Whilst increased expression may promote senescence and reduce tumourigenesis, our data suggest that the preponderance of KRAS mutations in human cancers is not due to an oncogenically optimal low relative endogenous expression level of KRAS versus the other Ras isoforms.